Question 1

What is VYKAT XR?

Accepted Answer

VYKAT XR is a Other.

Question 2

How often does VYKAT XR appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was VYKAT XR first tracked by Ergen?

Accepted Answer

First tracked on Apr 06, 2026.

Question 4

When was VYKAT XR last mentioned in news?

Accepted Answer

Last active on Apr 06, 2026.

Question 5

What is VYKAT XR's current news sentiment?

Accepted Answer

Aggregate sentiment score: 80 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is VYKAT XR in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving VYKAT XR?

Accepted Answer

Neurocrine Acquires Soleno for $2.9B (Apr 06, 2026, 6 articles).

Question 8

How did the "Neurocrine Acquires Soleno for $2.9B" event impact VYKAT XR?

Accepted Answer

VYKAT XR is the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, and its successful launch and strong revenue generation make it a valuable asset in the acquisition of MiNK Therapeutics by Neurocrine Biosciences.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.